Group 1 - The medical beauty sector increased by 0.4% on January 12, with Ai Meike leading the gains [1] - The Shanghai Composite Index closed at 4165.29, up 1.09%, while the Shenzhen Component Index closed at 14366.91, up 1.75% [1] - The trading volume and turnover for Ai Meike were 44,900 shares and 6.76 billion yuan, respectively [1] Group 2 - The net outflow of main funds in the medical beauty sector was 50.50 million yuan, while retail funds saw a net inflow of 24.49 million yuan [1] - The detailed fund flow for individual stocks showed significant net outflows for *ST Meigu and Jinbo Biological, with net outflows of 7.42 million yuan and 39.56 million yuan, respectively [2] - Ai Meike experienced a net outflow of 34.20 million yuan from main funds, indicating a 5.06% decrease in net shareholding [2]

来源：陕西都市快报 2021年，西安的李女士在西安高新区壹玖瑞娜医疗美容门诊部花费三万多元，想去除颈部皱纹，可术后 不仅皱纹未消，反而开启了漫长的修复之路。 李女士："注射后颈纹没消下去，脖子上反而出现了一条条肉条。我多次过来询问原因，想知道怎么会 变成这样，他们也说不出具体缘由，只说会继续帮我修复。" 从2021年起，李女士便在这家门诊部进行颈部横纹修复，前后共修复了6次，但截至目前，她颈部的横 纹依旧清晰可见，完全未达到该美容机构承诺的效果。 李女士："他们先是帮我去除肉条，再进行填充，来来回回还是老样子。我多次找医院协商，结果越修 复情况越严重。我再也不想在这修复了，已经完全不信任他们了。" 2025年4月，李女士在完成第六次修复后，效果仍不理想，于是要求壹玖瑞娜医疗美容门诊部提供此前 颈纹注射填充及六次修复的全部病历。但该门诊部迟迟未能提供，双方沟通时发生冲突，陪同李女士前 往的朋友也因此受伤。 李女士："我带着朋友去医院要病历，他们拒不提供，突然冲出来好几个人把我朋友打成了骨折，这件 事让我非常气愤。" 冲突发生后，辖区派出所介入调查，壹玖瑞娜医疗美容门诊部随后才提供了相关病历，但李女士对这些 病历 ...

Group 1 - The medical beauty sector increased by 2.39% on January 9, with Ai Meike leading the gains [1] - The Shanghai Composite Index closed at 4120.43, up 0.92%, while the Shenzhen Component Index closed at 14120.15, up 1.15% [1] - Key stocks in the medical beauty sector showed varied performance, with Ai Meike closing at 149.91, up 2.69%, and *ST Meigu closing at 3.34, down 1.18% [1] Group 2 - The medical beauty sector saw a net inflow of 192.35 million yuan from main funds, while retail investors experienced a net outflow of 3038.42 million yuan [1] - Specific stock fund flows indicated that Huaxi Biological had a main fund net inflow of 11.58 million yuan, while Ai Meike had a net outflow of 3941.60 million yuan from retail investors [2] - *ST Meigu had a significant net outflow of 1095.28 million yuan from main funds, but a net inflow of 956.07 million yuan from retail investors [2]

Group 1 - The medical beauty sector increased by 0.6% on January 8, with Huaxi Biological leading the gains [1] - The Shanghai Composite Index closed at 4082.98, down 0.07%, while the Shenzhen Component Index closed at 13959.48, down 0.51% [1] - The trading volume and turnover for key stocks in the medical beauty sector were reported, with Huaxi Biological closing at 45.11, up 1.12% [1] Group 2 - The net inflow of main funds in the medical beauty sector was 21.5 million yuan, while retail funds experienced a net outflow of 16.96 million yuan [1] - Detailed fund flow data showed that Aimeike had a main fund net inflow of 15.25 million yuan, while Huaxi Biological had a net inflow of 13.26 million yuan [2] - ST Meigu experienced a significant net outflow of main funds at 7.01 million yuan, indicating a negative trend in investor sentiment [2]

转自：劳动午报 当你在网络平台搜索"个性穿孔"，琳琅满目的工作室广告瞬间弹出，包括舌钉、唇钉、脐钉等不同项 目；当你在商场选购化妆品，却发现不少商品缺少明确的生产信息，标签内容模糊不清；当你路过美容 店，随手接过的宣传单上竟写着"皮肤管理可治疗抑郁症"……如今，人们对美的追求日益多元，美容项 目层出不穷，但这些服务背后，是否藏着不为人知的风险？近年来，贵州省贵阳市检察机关积极履行公 益诉讼检察职责，聚焦医疗美容和化妆品等领域开展法律监督，切实守护人民群众的"颜值安全"。（1 月1日《法治日报》） （来源：劳动午报） □邰怡明 ...

Core Viewpoint - Wang Sicong's era of indulgence is coming to an end as his investment ventures face significant challenges and setbacks [3][22]. Group 1: Recent Developments - Wang Sicong's investment company, Beijing Pusi Investment Co., Ltd., is publicly auctioning an 8% stake in Maiji Culture, valued at -166.62 thousand yuan, with a starting bid of over 100 thousand yuan [4][23]. - He has entered the medical beauty sector by co-founding a new clinic named "Beijing Ningyue Yiji Medical Beauty Clinic" alongside actors Qin Lan and Gan Wei, indicating a shift in investment focus [4][23]. Group 2: Investment History - Wang Sicong began his entrepreneurial journey with 500 million yuan provided by his father, Wang Jianlin, as a "trial and error" fund [5][25]. - His initial foray into the investment world included the establishment of Pusi Capital, which has since invested in over 90 companies across various sectors, including gaming, live streaming, and entertainment [17][37]. Group 3: Notable Achievements and Setbacks - Wang's iG esports club won the first championship for China in the DOTA2 International Invitational in 2012, earning a prize of 1 million USD, which was distributed among the team [7][27]. - The peak of his success came in 2018 when the Chinese esports industry reached nearly 90 billion yuan, coinciding with iG's championship win [12][32]. - However, following this peak, iG failed to maintain its success, and by 2019, Wang's company Panda Live faced bankruptcy, resulting in a 2 billion yuan loss for Pusi Capital [15][35]. Group 4: Current Challenges - As of 2024, Wang's business portfolio has significantly contracted, with Pusi Capital's shares frozen by the court, leading to operational difficulties for several investments [17][36]. - In June 2025, he transferred his company, managing over 6 billion yuan in assets, to what is perceived as a desperate measure for liquidity [36][37]. Group 5: Investment Strategy Analysis - Analysts suggest that Wang Sicong's investment strategy is characterized by a focus on high-heat, low-depth ventures, often lacking thorough research into industry fundamentals [18][37]. - His approach has been described as "celebrity capital" rather than "industrial capital," leading to vulnerabilities when market conditions change [18][37].

Group 1 - The core viewpoint of the report by Industrial Securities indicates that the overall A-share market is expected to rise by 27.65% in 2025, with profit contribution at 5.29%, valuation contribution at 20.44%, and dividend contribution at 1.91% [1][6][9] - In the primary industry analysis, profit is identified as the "watershed" determining the performance of various sectors in 2025, with leading sectors such as non-ferrous metals, AI hardware (communication, electronics), new energy, and machinery showing significant profit contributions [1][6][9] - Conversely, sectors like consumer goods, real estate, and dividends are expected to lag, primarily due to profit drag [1][6][9] Group 2 - In the secondary industry analysis, sectors with higher growth rates generally have positive profit contributions, while industries such as military (aerospace equipment, ground weapons, military electronics), steel raw materials, and decoration show negative profit contributions, mainly driven by valuation [9][12][14] - The report highlights that in the Hong Kong stock market, most leading sectors also exhibit positive profit contributions, particularly in non-ferrous metals, agriculture, pharmaceuticals, chemicals, and machinery, while lagging sectors like social services and construction are primarily affected by profit drag [12][14] - The secondary industries in the Hong Kong stock market show a similar trend, with leading sectors having positive profit contributions, while industries like motorcycles, traditional Chinese medicine, and glass fiber are negatively impacted by profit drag [14]

Core Viewpoint - The implementation of the new VAT law in China starting January 1, 2026, has raised concerns regarding tax obligations for the medical beauty industry, particularly the removal of VAT exemptions for profit-driven medical beauty institutions [1][4]. Group 1: Tax Policy Changes - The new VAT law specifies that "medical services provided by medical institutions" are exempt from VAT, but this exemption does not apply to profit-driven medical beauty institutions [1][4]. - The removal of VAT exemptions is aimed at ensuring that profit-driven medical beauty institutions comply with tax regulations, rather than imposing a new tax burden on consumers [1][4]. Group 2: Industry Impact and Compliance Issues - The medical beauty industry has experienced rapid growth, with the market size exceeding 300 billion yuan and approximately 20,000 legal medical beauty institutions projected for 2024 [4]. - Despite previous VAT exemptions, compliance issues have been prevalent, with cases of tax evasion reported, indicating a need for clearer regulations and enforcement [3][4]. Group 3: Market Dynamics and Future Trends - The new VAT regulations are expected to accelerate the consolidation of the medical beauty market, pushing smaller institutions with lower profit margins to exit, while larger chains may gain market share due to their compliance capabilities [5][6]. - The adjustment in tax burdens may lead to price changes in medical beauty services, with lower-cost services likely to reflect the tax increase in their pricing, while high-end services may absorb the costs to maintain customer loyalty [5][6]. Group 4: Recommendations for Compliance - Medical beauty institutions are advised to adopt best practices for compliance, including using corporate accounts for all income, accurately categorizing services for tax purposes, and ensuring consistency in contracts and invoicing [6].

Core Viewpoint - The implementation of the new VAT law in China starting January 1, 2026, will require profit-oriented medical beauty institutions to pay VAT, which has sparked widespread discussion about tax implications in the medical beauty industry [1][5]. Group 1: Tax Policy Changes - The new VAT law specifies that "medical services provided by medical institutions" are exempt from VAT, but this exemption does not apply to profit-oriented medical beauty institutions [1][5]. - The adjustment in tax policy aims to promote fair competition and standardized development within the medical beauty industry, which has seen rapid growth and an increase in the number of institutions [5][6]. Group 2: Industry Growth and Compliance Issues - The medical beauty industry in China has surpassed a market size of 300 billion yuan, with approximately 20,000 legal medical beauty institutions expected by 2024 [5]. - Despite previous tax exemptions, many medical beauty institutions have been found to engage in tax evasion practices, such as underreporting income and misclassifying taxable services [3][4]. Group 3: Impact of New Regulations - The removal of VAT exemptions may lead to price adjustments in medical beauty services, with lower-cost services likely passing on the tax burden to consumers, while high-end services may absorb the costs to maintain customer loyalty [6][7]. - The new regulations are expected to accelerate industry consolidation, with smaller institutions potentially exiting the market due to increased compliance costs, while larger chains may gain market share [6][7]. Group 4: Compliance Transformation Strategies - Medical beauty institutions are advised to adopt several compliance strategies, including using corporate accounts for all income, accurately classifying services for tax reporting, and ensuring financial transparency [7]. - Strengthening financial controls and training staff on tax policies will be crucial for institutions to navigate the new regulatory landscape effectively [7].

证券之星消息，1月7日医疗美容板块较上一交易日下跌0.74%，*ST美谷领跌。当日上证指数报收于 4085.77，上涨0.05%。深证成指报收于14030.56，上涨0.06%。医疗美容板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日医疗美容板块主力资金净流出2679.3万元，游资资金净流入1374.35万元，散户 资金净流入1304.95万元。医疗美容板块个股资金流向见下表： | 代码 | 名称 | 主力净流入 (元) | | | | 主力净占比 游资净流入 (元) 游资净占比 散户净流入 (元) 散户净占比 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 920982 锦波生物 | | | 2755.02万 | 12.55% | -1248.51万 | -5.69% | -439.98万 | -2.00% | | 688363 华熙生物 | | | 204.38万 | 1.30% | 771.92万 | 4. ...